Company Overview and News

1
MyoKardia (MYOK) CEO Tassos Gianakakos on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the MyoKardia Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator instructions] As a reminder, this call is being recorded.
MYOK

6
MyoKardia (MYOK) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks
MyoKardia (MYOK - Free Report) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.
MYOK VNOM COLL AKBA

1
MYOK / MyoKardia, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
myok-10q_20180630.htm UNITED STATES <
MYOK

1
MYOK / MyoKardia, Inc. 8-K (Current Report)

2018-08-08 sec.gov
myok-8k_20180808.htm UNITED STATES
MYOK

2
MYOK / MyoKardia, Inc. FORM 8-K (Current Report)

2018-06-15 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MYOK

37
Three Biotechs With Upcoming Data At Conferences

2018-06-11 seekingalpha
Biotech stocks tend to have strong movement when their respective companies have binary events upcoming in short order.
MYOK CYTK ARQL APR APRLY

113
Your Daily Pharma Scoop: Recent IPO And Offerings Review

2018-05-31 seekingalpha - 9
While we generally do not espouse IPO investing, this is a good place to start tracking interesting stocks early on.
INO CLLS ANIK MLNT SC GNCA CHRS ARDX CLXT CDTX ITRM ALXN MYOK KNSA EIGR IM PFNX

1
MYOK / MyoKardia, Inc. FORM 8-K (Current Report)

2018-05-28 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MYOK

1
MYOK / MyoKardia, Inc. 424B5 (Prospectus)

2018-05-28 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223526 CALCULATION OF REGISTRATION FEE
MYOK

2
MYOK / MyoKardia, Inc. 424B5 (Prospectus)

2018-05-21 sec.gov - 1
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223526 This prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. Neither this prospectus supplement nor the accompanying prospectus is an offer to sell
MYOK

2
MYOK / MyoKardia, Inc. 8-K (Current Report)

2018-05-21 sec.gov - 1
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MYOK

1
Myokardia's (MYOK) CEO Jack Clem on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen and welcome to the MyoKardia First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we'll conduct a question-and-answer session and instructions will follow at that time. [Operator instructions] As a reminder, this conference call is being recorded.
MYOK

2
MYOK / MyoKardia, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov - 1
myok-10q_20180331.htm UNITED STATES
MYOK

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 62857M105